1.1 – General Pre Hospital Care
1.2 – Abdominal Pain (Non-Traumatic)
1.3 – Nausea & Vomiting
1.4 – Syncope
1.5 – Shock
1.6 – Anaphylaxis Allergic Reaction
1.7 – Adrenal Crisis
1.8 – Behavioral Health Emergencies
1.8 (S) – Pre-Hospital ED Coordination and Management of Psychiatric Patients
2.1 – Adult Pediatric Trauma Triage
2.2 – General Trauma
2.3 – Burns
2.4 – General Crush Injury
2.5 – Soft Tissue and Orthopedic Injuries
2.6 – Spinal Injury Assessment
2.7 – Traumatic Arrest
2.8 – Drowning Submersion Injury
2.9 – Poisoning Overdose Environmental Exposure
2.10 – Heat Emergencies 9:25
2.11 – Hypothermia Frostbite 9:25
2.12 – Head Injury Moderate & Severe TBI 9:25
2.13 – Bleeding Control (BCON) 9:25
2.14 – Hemorrhagic Shock
2.15 – Sexual Assault
3.1 – Altered Mental Status 9:25
3.2 – Stroke or Suspected Stroke
3.3 – Respiratory Distress
3.4 – Seizures 9:25
3.5 – Sepsis
3.6 – Hyperactive Delirium Syndrome with Severe Agitation 2025
4.1 – Pediatric Medication Emergency Dosing and Intervention Cards
4.2 – Childbirth and Related Obstetrical-Emergencies
4.3 – Newborn and Neonatal Assessment and Resuscitation
4.4 – Pediatric Altered Mental Status 9:25
4.5 – Pediatric Respiratory Distress, Failure or Arrest
4.6 – Pediatric Fever
4.7 – Pediatric Seizures 9:25
5.1 – Cardiac Arrest
5.2 – Bradycardia
5.3 – Tachycardia
5.4 – Pulmonary Edema and Cardiogenic Shock
5.5 – Chest Pain Acute Coronary Syndrome
5.5 (S) – Transport of Patients with Suspected AMI
7.1 – 12-Lead KCG 9:25
7.2 – Child Abuse and Neglect
7.3 – Crime Scene Management
7.3 (S) – Medical Response to a Crime Scene
7.4 – Vulnerable Adult Abuse, Neglect, or Exploitation
7.5 – CPAP
7.6 – Dead on Scene & Termination of Resuscitation 9:25
7.6 (S1)-Dead On Scene Supplement 3:26
7.6 (S2)-Pronouncement of Death Supplement 3:26
7.7 – Do Not Resuscitate
7.8 – Electrical Therapy 9:25
7.8 (S) – Double Sequential Defibrillation 9:25
7.9 – Airway Management
7.9 (S1) – Video Laryngoscopy
7.9 (S2) – Bougie
7.10 – Helmet Removal
7.11 – Impedance Threshold Device (ITD)
7.12 – Oxygen Administration
7.13 – Pain Management
7.13 (S) – Pain Management Supplement
7.14 – Patient Assessment
7.15 – Documentation and Patient Care Records
7.15 (S) – EPCR, PCR and Transfer of Care
7.16 – Patient Restraint 9:25
7.17 – Patient Procedural Sedation
7.18 – Pleural Decompression
7.19 – Refusal of Care; Adult and Minor
7.20 – Spinal Precautions
7.21 – Blood Glucose Level Testing
7.22 – Tourniquet Application
7.23 – Vascular Access and IV Fluid Therapy 9:25
7.24 – End Tidal Carbon Dioxide Monitoring
7.25 – MI-POST
7.25 (S) – Michigan Physician Order for Scope of Treatment
7.26 – Not Adopted
7.27 – Transport of Adult Ventilator Dependent Patient
7.28 – Left Ventricular Assist Device (LVAD) 2025
7.29 – Mechanical Chest Compression Device
7.30 – Active Compression Decompression Device
7.31 – Spit Hood
8.1 – Downgrade of Response
8.2 – Patient Prioritization and Use of Lights and Sirens 9:25
8.3 – Transport Destination and Diversion
8.3 (S) – Emergency Facilities Limitation Policy
8.4 – OB High Risk Delivery Transport Guidelines
8.5 – ALS and LALS Intercept:Transfer of Care
8.6 – Dispatch
8.6 (S1) – Emergency Medical Dispatch Provider Criteria for Endorsement
8.6 (S2) – Mike Echo Unit Treatment and Transport Coordination
8.7 – ALS to BLS Transfer of Care
8.8 – Air Ambulance Personnel Scope of Practice
8.9 – Helicopter Utilization
8.9 (S) – Transport Destination Map Guide
8.10 – Infection Control and Communicable Disease 9:25
8.11 – Immunization & Testing
8.12 – Communications Failure
8.12 (S) – Radio Incident Failure Report
8.13 – Electronic Records & EMS Information System
8.14 – Protected Health Information (PHI)
8.15 – Interfacility Patient Transfers
8.15 (S1) – Interfacility Pt Transfers and CC Pt Transports of Adult Non-Critical Vent Dependent Pt
8.15 (S2) – Critical Care Patient Transport Curriculum
8.15 (S3) – HHFNC Administration Adult and Pediatric
8.15 (S4) – NTG and Heparin Drip Interfacility
8.16 – Licensure Level Requirement of Attendant During Transport
8.16 (S) – Life Support Unit Personnel Staffing: Alternate Staffing
8.17 – Medical Control Privileges
8.17 (S1) – Pre-Hospital Equipment Responsibility
8.17 (S2) – Additional Equipment and Training
8.18 – Responsibilities of the Participants in the MCA System
8.19 – On Scene Physician Interaction
8.19 (S) – Scene and Patient Management Policy
8.20 – Protocol Deviation
8.21 – Violent: Chemical: Hazardous Scene
8.22 – Medical Examiner Notification and Body Disposition
8.23 – Safe Delivery of Newborns
8.24 – Complaint Investigation & Resolution
8.25 – Disciplinary Action Appeal
8.26 – EMS Provider Criminal Charges and Convictions
8.27 – Quality Improvement Program
8.27(S) Integrated Agency System PSRO QI Plan 3:26
8.28 – Not Adopted
8.29 – General Operations
8.29 (S1) – Access to HEMS Communication System
8.29 (S2) – EMS Communications Interoperability
8.29 (S3) – Transfer of Care
8.30 – Hospice Patient Coordination of Services
8.30 (S) – Hospice Patient Management
8.31 – Alternative EMS Response Team
8.31 (S) – Special Event Medication Drug Box
9.1 – Medication Administration 9:25
9.2 – Medication Substitution – Discontinued
9.3 – Medication Shortage 9:25
9.4 – Personal Metered Dose Inhaler Use
9.5 – IV Ancillary Supply Exchange
9.6 – SE Michigan Medication Exchange and Replacement 2025
9.6 Addendum – SEM Medication Exchange Addendum June 2025
9.6 (S1) – MFRBLS Naloxone Kit Contents and Exchange Procedure
9.6 (S2) – BLS Nebulized Bronchodilator Kit Contents and Exchange Procedure
9.6 (S3) – MFR & Basic EMT EPI KIT Contents and Exchange Procedure
9.7 – Not Adopted
9.8 – 9.8 Naloxone Leave Behind Medication Kit Contents and Distribution Procedure 3:26
9.9 – Medications General
9.10 – Acetaminophen
9.11 – Adenosine
9.12 – Albuterol
9.13 – Amiodarone
9.14 – Aspirin
9.15 – Atropine
9.16 – Calcium Chloride
9.17 – Cefazolin
9.18 – Ceftriaxone
9.19 – Dextrose 9:25
9.20 – Diazepam
9.21 – Diltiazem
9.22 – Diphenhydramine
9.23 – Epinephrine
9.24 – Fentanyl
9.25 – Glucagon 9:25
9.26 – Hydroxocobalamin
9.27 – Ibuprofen
9.28 – Ipratropium Bromide
9.29 – Ketamine
9.30 – Ketorolac
9.31 – Lidocaine
9.32 – Magnesium Sulfate
9.33 – Methylprednisolone
9.34 – Midazolam
9.35 – Morphine
9.36 – Naloxone
9.37 – Nitroglycerin
9.38 – Ondansetron
9.39 – Pralidoxime
9.40 – Prednisone
9.41 – Sodium Bicarbonate
9.42 – Racepinephrine
9.43 – Tetracaine
9.44 – Tranexamic Acid
9.45 – Verapamil
9.46 – Cardizem
9.47 – Acetylcysteine
9.48 – Magnesium Sulfate (Interfacility Transfer)
9.49 – Tissue Plasminogen Activator
9.50 – Octreotide
9.51 – Furosemide
9.52 – Levetiracetam
9.53 – Blood Products
9.54 – Glycoprotein Receptor Antagonist
9.55 – 2-Pam Chloride:Duodote
9.56 – Dopamine
9.57 – Hydromorphone
9.58 – Lorazepam
10.1 – General CBRNE Identification of Agents
10.2 – Chemical Exposure
10.3 – Nerve Agent: Organophosphate Pesticide Exposure Treatment
10.4 – CHEMPACK : MEDDRUN
10.5 – Cyanide Exposure
10.6 – Mass Casualty Incidents
10.6 (S) – Multiple Patients Incidents – Quick Guide
10.7 – Pre-Hospital (EMS) MCA Mutual Aid during Disaster
10.7 (S) – Wayne:Monroe County Coordination of Services and Transportation Agreement
10.8 – Hazard Contaminated Patient
10.9 – Suspected Pandemic
10.10 – SPRN Transport and Destination Guidelines
10.11 – SPRN Patient Containment Algorithm
10.12 – SPRN Transport Supplies
10.13 – SPRN Transport Procedure
10.14 – SPRN Patient Care during Transport of Suspected Highly Infectious Agent
10.15 – SPRN Ambulance Cleaning and Disinfection
10.16 – SPRN Medical Isolation Transport Device
10.17 – SPRN Team Selection Procedure
10.18 – SPRN Death during Transport
10.19 – Hazardous Material Procedure
10.20 – Hazardous Materials – Medical Treatment
10.21 – Radiation Emergency Procedure
11.1 – General Hazmat 2025
11.2 – Ammonia 2025
11.3 – Asphyxiants 2025
11.4 – Chlorine and Related Compounds 2025
11.5 – Corrosive Agents 2025
11.6 – Hazmat Cyanide Exposure 2025
11.7 – Hazmat Eye Irrigation 2025
11.8 – Hydrocarbons 2025
11.9 – Hydrogen Fluoride 2025
11.10 – Hydrogen Sulfide Sulfides and Mercaptans 2025
11.11 – Methemoglobinemia 2025
11.12 – Organophosphate Poisoning 2025
11.13 – Hazmat Medication Exchange and Replacement Procedure 2025
11.14 – HazMat Cyanokit Medication Kit Exchange Use Replacement 2025
12.1 – USAR General Protocol
12.1 (S) – CQI PSRO Reporting
12.2 – USAR Training Requirements
12.3 – USAR Medical Control
12.4 – USAR Dispatch
12.5 – USAR Medication Box
12.5 (S) – USAR Medication Box Contents
12.6 – USAR Airway Dust Impaction
12.7 – USAR Blast Injury
12.8 – USAR Compartment Syndrome
12.9 – USAR Crush Injury Syndrome
12.10 – USAR Ocular Trauma
12.11 – USAR Broad Spectrum Antibiotics
12.12 –USAR FIELD AMPUTATION
12.13 – Still awaiting approval
12.14 – USAR Blood Draw
12.15 – USAR Field Fasciotomy
13.0 – Table of Contents
13.2 – HEMS-Abbreviations-Guide-Update-8-Mar-2018
13.3 – Electronic PCR – ED Fax / eMail Transmission Routes
13.4 – Phone Numbers for DHS and Protective Services
13.5 – DEMCA Destination Matrix
13.6 – Patient Field Note
13.7 – Transfer of Care Information Form
14.0 – Table of Contents
14.1 – EMS Agency Criteria for Endorsement
14.2 – Letter of Compliance – Parts 1 & 2
14.3 – Pharmacy Exchange Memorandum of Understanding
14.4 – Alternate ALS Staffing Request Form – Update 28 June 2019
14.5 – 12-Lead Program Application for Endorsement – BLS Update 21 Jun 2019
14.6 – Inter-Facility Critical Care Transport Application for Endorsement – 1 May 2019
14.7 – Emergency Medical Dispatch Provider Application for Endorsement
14.8 – Medical Control Hospital Criteria for Endorsement
14.9 – Online MC Hospital Letter of Compliance
14.10 A – Non-Medical Control Facility Criteria for Endorsement
14.10 B – Designation of Non-Medical Control Facilities
14.11 – Non-Medical Control Care Facility Annual Letter of Compliance
14.14 – BLS Nebulized Bronchodilator Optional Program Application for Endorsement
